Preclinical pharmacology of alogabat: a novel GABAA-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABAA signaling.
Saved in:
| Title: | Preclinical pharmacology of alogabat: a novel GABA |
|---|---|
| Authors: | Cecere G; Medicinal Chemistry, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Ballard TM; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Knoflach F; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Honer M; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Hipp JF; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Garces P; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Mueggler T; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Künnecke B; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Bruns A; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Prinssen EP; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Schoenenberger P; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Janz P; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Redondo R; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Biemans B; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Knust H; Medicinal Chemistry, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Olivares-Morales A; Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Brigo A; Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Schulz JM; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Bertrand D; HiQScreen Sàrl, Vésenaz, Switzerland., Saxe M; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., O'Connor EC; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Hernandez MC; Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2025 Jul 21; Vol. 16, pp. 1626078. Date of Electronic Publication: 2025 Jul 21 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2025.1626078 |
